Is ImmuPharma PLC halal to invest in?

According to Musaffa's Shariah screening methodology, ImmuPharma PLC (IMM.L) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is ImmuPharma PLC a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ImmuPharma PLC using these criteria to determine its compliance status.

Can Muslims buy shares of ImmuPharma PLC?

Muslim investors may consider investing in ImmuPharma PLC if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is ImmuPharma PLC classified as NOT HALAL?

Musaffa determines the Shariah status of ImmuPharma PLC by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for ImmuPharma PLC updated?

The Shariah compliance status of ImmuPharma PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like ImmuPharma PLC become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of ImmuPharma PLC?

You can check the latest Shariah compliance status of ImmuPharma PLC on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ImmuPharma PLC IMM.L

GBX4.46 GBX0.23 (5.42%) 1D

Last Updated: May 15, 12:00 AM·LSE

IMM.L Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: January 24, 2026

Report Source: 2025 2nd Quarter Report

Analyst's Ratings for ImmuPharma PLC (IMM.L)

Based on 8 analysts giving stock ratings to ImmuPharma PLC in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

ImmuPharma PLC. Stock Analysis IMM.L

United Kingdom Health Care Nano Cap Report: Q2, 2025

ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. The firm is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. The company is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.

Key Statistics of ImmuPharma PLC (IMM.L)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

GBX4.15GBX4.46

Today's Open

GBX4.23

Volume

26.99K

P/E Ratio (TTM)

52 Week Range

GBX1.40GBX19.00

Market Cap

2.58B

Avg. Volume

169.77K

Dividend Yield

Financial Metrics & Statements of ImmuPharma PLC (IMM.L)

FAQ's for ImmuPharma PLC (IMM.L)

According to Musaffa’s Shariah screening methodology, ImmuPharma PLC (IMM.L) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.